• 1. The role of metallothionein-3 in streptozotocin-induced beta-islet cell death and diabetes in mice
  Hyae-Ran Byun,Jeong A Choi,Jae-Young Koh Metallomics 2014 6 1748
• 2. Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model
  Yangyang Zhu,Tian Teng,Hu Wang,Hao Guo,Lei Du,Baoxue Yang,Xiaoxing Yin,Ying Sun Food Funct. 2018 9 389
• 3. Local remodeling of synthetic extracellular matrix microenvironments by co-cultured endometrial epithelial and stromal cells enables long-term dynamic physiological function
  Christi D. Cook,Abby S. Hill,Margaret Guo,Linda Stockdale,Julia P. Papps,Keith B. Isaacson,Douglas A. Lauffenburger,Linda G. Griffith Integr. Biol. 2017 9 271
• 4. Local remodeling of synthetic extracellular matrix microenvironments by co-cultured endometrial epithelial and stromal cells enables long-term dynamic physiological function
  Christi D. Cook,Abby S. Hill,Margaret Guo,Linda Stockdale,Julia P. Papps,Keith B. Isaacson,Douglas A. Lauffenburger,Linda G. Griffith Integr. Biol. 2017 9 271
• 5. A monitoring system for axonal growth dynamics using micropatterns of permissive and Semaphorin 3F chemorepulsive signals
  Jae Ryun Ryu,June Hoan Kim,Hyo Min Cho,Youhwa Jo,Boram Lee,Sunghoon Joo,Uikyu Chae,Yoonkey Nam,Il-Joo Cho,Woong Sun Lab Chip 2019 19 291

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides 3',5'-cyclic purine nucleotides
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides Cyclic purine nucleotides 3',5'-cyclic purine nucleotides

Exploring the Properties and Applications of 8-Bromoadenosine 3',5'-Cyclic Monophosphate (CAS No. 23583-48-4)

The compound 8-Bromoadenosine 3',5'-Cyclic Monophosphate (commonly abbreviated as 8-Br-cAMP) is a modified nucleotide derivative with the CAS registry number 23583-48-4. This compound has garnered significant attention in the fields of biochemistry, pharmacology, and molecular biology due to its unique structural properties and functional roles in cellular signaling pathways. The molecule is a brominated derivative of cyclic adenosine monophosphate (cAMP), a key second messenger in various cellular processes. The introduction of the bromine atom at the 8-position of the adenine ring introduces distinct chemical and biological properties, making it a valuable tool for research and potential therapeutic applications.

Structural Insights and Synthesis

8-Bromoadenosine 3',5'-Cyclic Monophosphate is synthesized through a series of chemical modifications starting from adenosine. The bromination occurs at the 8-position of the adenine moiety, which is a site that is not typically occupied by hydrogen in naturally occurring nucleotides. This substitution imparts unique electronic and steric properties to the molecule, influencing its interactions with proteins and enzymes. The synthesis of this compound involves multi-step organic reactions, including protection/deprotection strategies to ensure high purity and stability.

Recent advancements in synthetic methodologies have enabled the scalable production of 8-Br-cAMP, making it more accessible for large-scale studies. Researchers have also explored green chemistry approaches to minimize environmental impact during synthesis, aligning with current sustainability goals in pharmaceutical chemistry.

Biological Functions and Signaling Pathways

In biological systems, cAMP serves as a critical second messenger, transducing extracellular signals into intracellular responses. The presence of bromine in 8-Br-cAMP confers enhanced stability compared to its non-brominated counterpart, allowing it to persist longer within cells. This extended half-life enables prolonged modulation of downstream signaling pathways, particularly those involving protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC).

Studies have demonstrated that 8-Bromoadenosine 3',5'-Cyclic Monophosphate can activate PKA more effectively than native cAMP due to its resistance to hydrolysis by phosphodiesterases. This property makes it an invaluable tool for investigating PKA-dependent processes, such as gene expression regulation, ion channel gating, and cell cycle progression.

Moreover, 8-Br-cAMP has been shown to influence other cAMP-sensitive targets beyond PKA, including certain ion channels and transcription factors. Its ability to modulate diverse signaling cascades underscores its versatility as a research reagent and potential therapeutic agent.

Therapeutic Potential and Research Directions

The pharmacological profile of 8-Bromoadenosine 3',5'-Cyclic Monophosphate has positioned it as a promising candidate for various therapeutic applications. Preclinical studies have highlighted its potential in treating neurological disorders such as Alzheimer's disease and Parkinson's disease by enhancing cognitive function and mitigating neurodegeneration.

In addition, 8-Br-cAMP has demonstrated anti-inflammatory properties by modulating immune cell activity through cAMP-dependent pathways. This suggests its potential utility in inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Recent research has also explored the use of 8-Bromoadenosine 3',5'-Cyclic Monophosphate in cancer therapy. By targeting cAMP signaling pathways that are often dysregulated in cancer cells, this compound may offer new avenues for developing targeted therapies with fewer side effects compared to conventional chemotherapeutic agents.

Safety Profile and Toxicological Considerations

Evaluating the safety profile of 8-Bromoadenosine 3',5'-Cyclic Monophosphate is crucial for its translation into clinical applications. Acute toxicity studies have indicated that this compound exhibits low toxicity at therapeutically relevant doses. However, chronic exposure studies are still required to fully understand its long-term safety implications.

Biodistribution studies have shown that 8-Br-cAMP accumulates predominantly in tissues with high metabolic activity, such as the liver and brain. This tissue-selective distribution may be advantageous for targeting specific pathologies while minimizing systemic side effects.

Efforts are currently underway to optimize delivery systems for 8-Bromoadenosine 3',5'-Cyclic Monophosphate, including encapsulation within nanoparticles or liposomes. These strategies aim to enhance bioavailability, reduce off-target effects, and improve therapeutic efficacy.

Future Prospects

The Future of 8-Bromoadenosine 3',5'-Cyclic Monophosphate: Emerging Trends

• 129735-00-8(Adenosine, 8-bromo-,cyclic 3',5'-[hydrogen [P(R)]-phosphorothioate] (9CI))
• 32465-18-2(9H-Purin-6-amine,9-(3,5-O-phosphinico-b-D-arabinofuranosyl)- (9CI))
• 143832-09-1(Ppp-AA)
• 123334-12-3(8-Bromoadenosine 3',5'-Cyclic Monophosphate Sodium Salt Monohydrate)
• 114697-05-1(Siloxanes and Silicones, lauryl Me, Me hydrogen, Me 3-(oxiranylmethoxy)propyl, Me 2-phenylpropyl)
• 60-92-4(Cyclic AMP)
• 24493-93-4(9H-Purin-6-amine,9-(3,5-O-phosphinico-b-D-xylofuranosyl)- (9CI))
• 23600-16-0(Adenosine 5'-(trihydrogen diphosphate), 8-bromo- (9CI))
• 23583-49-5(2'-Adenylic acid,8-bromo- (9CI))
• 23567-96-6(8-Bromo-AMP)